Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01617629 · ClinicalTrials.gov registry record · Phase 2
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
A Phase 2 study of Epithelial Ovarian Cancer, sponsored by Prima BioMed.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 6
- Study locations
NCT01617629: Completed Phase 2 study of Epithelial Ovarian Cancer, sponsored by Prima BioMed.
NCT01617629 is a Phase 2 study of Epithelial Ovarian Cancer that has completed, run by Prima BioMed. The registered enrollment target is 9 participants, below the 211-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01617629, a Phase 2 study of Epithelial Ovarian Cancer, has completed, sponsored by Prima BioMed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer eligible for study participation due to disease progression.
Primary Outcome
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the drug. A SAE is any untoward medical occurrence that at any dose: results in de
Conditions Studied
Interventions
- BIOLOGICAL MUC1 Dendritic Cell Vaccine (Cvac)
Study Locations (6)
California
- Marin Cancer Care, Inc. - Greenbrae
- Scripps Cancer Center - La Jolla
Florida
- Collaborative Research Group - Boca Raton
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Washington
- University of Washington Medical Center - Seattle
Queensland
- Greenslopes Private Hospital - Greenslopes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
What the finished NCT01617629 record still lists
NCT01617629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 211-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Epithelial Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which MUC1 Dendritic Cell Vaccine (Cvac) is the first listed.
NCT01617629 lists 6 locations in 5 states (California, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT01617629 about?
NCT01617629 is a clinical study titled "Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study". The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer eligible for study participation due to disease progression.
What is the current status of trial NCT01617629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2011-12. Estimated completion is 2014-04.
What conditions does trial NCT01617629 study?
This clinical trial studies the following conditions: Epithelial Ovarian Cancer.
What interventions are being tested in trial NCT01617629?
The interventions under investigation include: MUC1 Dendritic Cell Vaccine (Cvac) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01617629?
This trial is sponsored by Prima BioMed, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01617629 being conducted?
This trial has 6 study locations across California, Florida, Indiana, Washington, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelial Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01617629's enrollment target sits among peer trials
9 41st of 41 higher than 1 of 41 other Epithelial Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epithelial Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Isoquercetin in People With Ovarian Cancer
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
-
HOT: HIPEC in Ovarian Cancer as Initial Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
COMPLETED · Phase 2
-
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia